Eiko Lifesciences Ltd
Incorporated in 2021, Eiko LifeSciences
Ltd manufacturing & sells Specialty
Chemical and Fine Chemicals[1]
- Market Cap ₹ 75.8 Cr.
- Current Price ₹ 60.9
- High / Low ₹ 81.3 / 45.1
- Stock P/E
- Book Value ₹ 41.2
- Dividend Yield 0.00 %
- ROCE -103 %
- ROE -48.5 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Debtor days have improved from 113 to 39.8 days.
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 24.4%
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | |
|---|---|---|---|
| 2.36 | 4.27 | 10.81 | |
| 1.98 | 4.95 | 15.29 | |
| Operating Profit | 0.38 | -0.68 | -4.48 |
| OPM % | 16.10% | -15.93% | -41.44% |
| 0.04 | 0.04 | 0.09 | |
| Interest | 0.09 | 0.19 | 0.35 |
| Depreciation | 0.08 | 0.17 | 0.19 |
| Profit before tax | 0.25 | -1.00 | -4.93 |
| Tax % | 20.00% | -21.00% | -26.77% |
| 0.20 | -0.78 | -3.62 | |
| EPS in Rs | 0.31 | -0.69 | -2.98 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 153% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -334% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | -4% |
| 1 Year: | -5% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -49% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Sep 2024 | |
|---|---|---|---|---|
| Equity Capital | 3.82 | 3.82 | 3.82 | 12.87 |
| Reserves | 1.74 | 1.10 | -0.87 | 38.46 |
| 1.74 | 1.37 | 1.61 | 0.43 | |
| 3.66 | 3.01 | 7.49 | 3.17 | |
| Total Liabilities | 10.96 | 9.30 | 12.05 | 54.93 |
| 1.68 | 1.71 | 1.75 | 13.08 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 3.17 | 1.72 | 0.10 | 7.06 |
| 6.11 | 5.87 | 10.20 | 34.79 | |
| Total Assets | 10.96 | 9.30 | 12.05 | 54.93 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | |
|---|---|---|---|
| 0.00 | 0.16 | -0.33 | |
| 0.00 | -0.30 | -0.71 | |
| 0.00 | -0.55 | 0.95 | |
| Net Cash Flow | 0.00 | -0.69 | -0.09 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | |
|---|---|---|---|
| Debtor Days | 225.81 | 73.51 | 39.84 |
| Inventory Days | 819.93 | 287.76 | 136.40 |
| Days Payable | 605.69 | 174.40 | 163.59 |
| Cash Conversion Cycle | 440.04 | 186.87 | 12.65 |
| Working Capital Days | 267.56 | 78.64 | -145.86 |
| ROCE % | -11.83% | -102.92% |
Documents
Announcements
-
Revised Outcome Of Right Issue Committee Meeting
1d - Approval of Final Reminder Cum Forfeiture Notice for shareholders.
-
Outcome Of The Meeting Of The Right Issue Committee Of Board Of Director Held On 25Th September, 2024
1d - Approval of Final Reminder Cum Forfeiture Notice.
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
1d - Lenus Finvest acquired 9,52,385 shares of Eiko Lifesciences.
-
Board Meeting Intimation for Discussion On Final Reminder And Forfeiture Of The Partly Paid-Up Equity Shares On Which Call Money Has Not Been Received By The Company.
19 Nov - Meeting to discuss forfeiture of partly paid-up shares.
-
Post-Offer Public Announcement
12 Nov - Lenus Finvest announces open offer for Eiko Lifesciences.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
ELL is in the business of manufacturing, processing, formulating, producing, buying, selling, and exporting specialty and Fine Chemicals comprising organic & inorganic chemicals, and Pharma Intermediates, etc.